Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2013

View Archived Issues

Development of a potassium channel activator for the treatment of migraine

Novel phosphate adsorbers for the treatment of patients with renal failure

miRNA improves survival in a murine model of ALS

Development of two novel murine models of filarial pathology

Biotest and EpiVax to develop non-immunogenic treatment for hemophilia A

Stallergenes and ActoGeniX to develop treatments for allergic diseases

OncoMed and Celgene sign agreement for anti-cancer stem cell product candidates

Anti-infective startup company Auspherix launched

RXi Pharmaceuticals reports additional data from phase I RXI-109 trial

Genentech begins phase II trial of DNIB-0600A

Novel Nampt inhibitors presented by AbbVie

Novel muscarinic M4 positive allosteric modulator for the treatment of Huntington's disease

Incyte Corp. presents new JAK1 inhibitors

Researchers at Actelion Pharmaceuticals synthesize novel LXA4 receptor agonists

Idera Pharmaceuticals opens enrollment in phase I/II trial of IMO-8400

Glenmark Pharmaceuticals discloses novel ROR-gamma modulators

GlaxoSmithKline patents new EZH2 inhibitors for cancer

Bristol-Myers Squibb synthesizes new GPR119 receptor agonists

3-V Biosciences begins phase I TVB-2640 trial

Galapagos reports phase I findings on GLPG-1205

Sanofi launches ComPlavin combination tablets in Japan

Topline data reported from phase II study of ChemoCentryx's CCX-168

FDA grants orphan drug designation to Immunomedics' IMMU-132 for SCLC

The Medicines Company gains anti-infective assets through Rempex acquisition

Puma Biotechnology reports data from I-SPY 2 trial of neratinib

OncoMed studies vantictumab combination therapy for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...